HAVCR2 and neoplasm: In addition, targeting TIM-3 with PD-1 in preclinical settings has shown a synergistic effect by reinvigorating T cell function and increasing anti-tumor immunity (Sakuishi et al., 2010; Koyama et al., 2016).